Patients with decompensated
cirrhosis, particularly those with
acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with
simvastatin and
rifaximin on plasma metabolites of patients with decompensated
cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated
cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE-SAFETY randomized, double-blind, placebo-controlled trial treated with
simvastatin 20 mg/day plus
rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography-tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and
lipid alterations, specifically in pathways associated with
inflammation and
mitochondrial dysfunction, such as the
tryptophan-
kynurenine and
carnitine beta-oxidation pathways. An ACLF-specific signature was identified. Treatment with
simvastatin and
rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the
tryptophan-
kynurenine and
carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with
simvastatin and
rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with
simvastatin and
rifaximin in decompensated
cirrhosis and sets the stage for the use of metabolomics to investigate new targeted
therapies in
cirrhosis to prevent ACLF development.